Molecular mechanisms behind the defects in insulin production and secretion associated with antihuman immunodeficiency virus (anti-HIV) therapy and the development of HIV-associated lipodystrophy syndrome (HALS) are discussed in this article. Data suggesting insulin resistance on the beta cell and defects in first-phase insulin release of HALS patients are presented. Hepatic extraction of insulin, nonglucose insulin secretagogues and insulin-like growth factor release may exert influence on the demand of circulating insulin and on insulin secretion in HIV-infected patients. Finally, the paucity in understanding the incretin effects in HIV and HIV therapy in relation to insulin secretion is highlighted.
Keywords: Antiretroviral therapy; Incretins; Insulin secretion; Insulin-like growth factors; Lipodystrophy; Nonglucose insulin secretagogues; Prehepatic; Proinsulin.
Copyright © 2014 Elsevier Inc. All rights reserved.